Skip to main content

Coronavirus (COVID-19) Updates: Visitation Policies (New! 11.25.20) | How We're Keeping You Safe | Latest COVID Information

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

A081105 Alchemist / EGFR positive, study of Erlotinib vs Observation/ Yuhchyau Chen

Research Question:
Does erlotinib treat patients with non-small cell lung cancer?

Basic Study Information

Purpose:
This phase III ALCHEMIST trial studies how well erlotinib hydrochloride compared to observation works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Location: Highland Hospital

Lead Researcher (Principal Investigator)

Lead Researcher:  Yuhchyau Chen

Study Contact Information

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search